Drug Resistance Found As Intestinal Tumor

Drug Resistance Found As Intestinal Tumor

15 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:

Bradley E. Bernstein, MD @BradEBernstein @willflavahan of @MassGeneralNews explains the cause of drug resistance found in a form of intestinal tumor.

___________

Most cases of gastrointestinal stromal tumor (GIST), a form of soft tissue cancer (sarcoma), are caused by gene mutations that can be treated effectively with drugs that inhibit the action of enzymes which promote rogue cancer.

But an estimated 10% to 20% of GISTs do not have any mutations detectable or targeted. Scientists in a partnership on cancer research in the Boston area have now explained mechanisms that allow the production of these hard-to-treat cancers and have identified approaches in laboratory experiments that could lead to successful new therapies.

The research, a joint effort by scientists at the Massachusetts General Hospital (MGH), the MIT and Harvard Broad Institute, the Dana-Farber Cancer Institute (DFCI) and the Harvard Medical School (HMS) Ludwig Center, is published in Nature journal.

Importantly, the investigators show how "epigenetic" changes - changes in how the code of genes is read by tumor cells that are not caused by genetic mutations - can lead to the development of GISTs and other cancers, and how it may be possible to short-circuit the cancer-causing machinery.

"Your genome consists of about 6 feet of DNA wrapped very carefully to fit into microscopic cells. One of the tricks that the cell uses to compact all of this DNA is to tie it up into little loops," says senior co-author Bradley E. Bernstein, MD, PhD, of MGH, Broad Institute and the Ludwig Center at Harvard.

He prefers the method of shoelaces, where a knot separates every carefully tied chain. In scientific terms, the "knot" in the cells is called an "insulator." He and his colleagues found that one of these insulators usually prevents a gene that causes cancer, FGF4, from coming into contact with a stretch of DNA with a powerful switch that turns on an unrelated gene. The cancer-causing gene and the shift are in different loops in normal cells and never come into contact with each other. The insulator is not active in some types of GIST, however, the loops combine into one, and the on-switch activates the cancer-causing FGF4 gene incorrectly.

Read here: https://www.oncologytube.com/video/cause-of-drug-resistance-found-in-a-form-of-intestinal-tumor

Up Next Autoplay
Drug Resistance Found as Instestinal Tumor: How This Affects Clinicians
Drug Resistance Found as Instestinal Tumor: How This Affects Clinicians
Category: Gastrointestinal Cancer
6 Views
Massachusetts General Hospital 1 month
Cause of Drug Resistance Found in a Form of Intestinal Tumor
Cause of Drug Resistance Found in a Form of Intestinal Tumor
Category: Gastrointestinal Cancer
11 Views
Massachusetts General Hospital 1 month
Intestinal Tumor Commonly Asked Questions
Intestinal Tumor Commonly Asked Questions
Category: Gastrointestinal Cancer
5 Views
Massachusetts General Hospital 1 month
KEYNOTE-062: Pembrolizumab in HER2-, PD-L1  Positive Advanced Gastric Cancer
KEYNOTE-062: Pembrolizumab in HER2-, PD-L1 Positive Advanced Gastric Cancer
Category: Gastrointestinal Cancer
175 Views
obr 5 months
When Do You Prescribe Bland Vs Chemo Or Radio Embolization: Chemo Embolization Has Not Caught On In Our Institution Because The Side Effects & Extra Months Of Durability Are Not Of Value
When Do You Prescribe Bland Vs Chemo Or Radio Embolization: Chemo Embolization Has Not Caught On In Our Institution Because The Side Effects & Extra Months Of Durability Are Not Of Value
Category: Gastrointestinal Cancer
218 Views
Annual-Meeting 6 months
Inducing Embolization Syndrome When Performing infarction: Not Uncommon To Take 4-8 Weeks To Get Over The Treatment Of Embolotherapy
Inducing Embolization Syndrome When Performing infarction: Not Uncommon To Take 4-8 Weeks To Get Over The Treatment Of Embolotherapy
Category: Gastrointestinal Cancer
27 Views
Annual-Meeting 6 months
Evaluating mTOR Inhibitor Everolimus With Embolotherapy: Objective Response Rate Of 57 We Did Not Stop Everolimus During Embolotherapy, We Continued It
Evaluating mTOR Inhibitor Everolimus With Embolotherapy: Objective Response Rate Of 57 We Did Not Stop Everolimus During Embolotherapy, We Continued It
Category: Gastrointestinal Cancer
126 Views
Annual-Meeting 6 months
Caring For Every Patient And Learning From Every Patient
Caring For Every Patient And Learning From Every Patient
Category: Gastrointestinal Cancer
159 Views
Annual-Meeting 6 months
The Quality and Completeness of Data
The Quality and Completeness of Data
Category: Gastrointestinal Cancer
115 Views
Annual-Meeting 6 months